Continues to Strengthen Its Pandemic Preparedness and Biodefense Vaccine Portfolio ATLANTA, GA - April 9, 2025 (NEWMEDIAWIRE) ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent 09.04.2025 / 15:07 CET/CEST The issuer is solely responsible ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed Additional data evaluating GEO-CM04S1 as ...

Q4 2024 Earnings Call Transcript March 27, 2025 GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.79. Operator: Good afternoon. And welcome everyone to the ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Reports 2024 Year-End Financial Results and Provides Business Update 27.03.2025 / 21:06 CET/CEST The issuer is solely responsible for the ...

GeoVax Labs (NASDAQ:GOVX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a ...

Investment analysts at Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a research note issued on ...

Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd ...

GeoVax Labs Inc. (GOVX), with a market capitalization of $12.2 million, reported its financial results for the full year 2024, revealing a net loss of $25 million, or $4.82 per share, on revenues of ...

Analysts anticipate Geovax Labs to report an earnings per share (EPS) of $-0.95. Investors in Geovax Labs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and ...